rurigo Nodularis (PN) is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution.
As per the Delveinsight, in 2017, the market size of Prurigo Nodularis in 7MM was USD 659.29 Million.
The total diagnosed prevalent population of Prurigo Nodularis in 7MM was 539,893 in 2017. Among the 7MM, the United States had the largest share of the total diagnosed prevalent population with ~46.30% of the total cases.
The key companies in the Prurigo Nodularis Market include Menlo Therapeutics, Trevi Therapeutics, Galderma, Amgen, Maruho, Kiniksa Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, and many others.
Source: Prurigo Nodularis Market Trends Analysis